Aclarion, Inc.
ACONHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeAclarion, Inc. operates as a healthcare technology company in the United States. At a $6.3M market cap, Aclarion, Inc. ranks as a micro-cap company within healthcare. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments.
Market Cap
$6.3M
Beta
1.21
P/E (TTM)
—
P/E (Fwd)
-0.46
EPS (TTM)
$-5.51
EPS (Fwd)
$-5.47
ROE
-45.4%
ROA
-28.8%
Cash
$19.0M
Total Debt
$0
Free CF
-$4.9M
52W Change
-65.9%
Annual Financials
Cash vs Debt
Where ACON stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ACON finished 26.04% below its 150-day moving average ($3.61) and 41.45% below its 200-day moving average ($4.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACON overbought or oversold?
At the July 15, 2026 close, ACON's RSI(14) was 39.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aclarion, Inc. reports $19.0M in cash and $0 in total debt. Free cash flow is running at -$4.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -45.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $60K (2022) to $76K (2025), reflecting a 25% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ACON.